---
title: "Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Dosing and administration questions"
description: "Dosing and administration questions on Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Administration, and Taking treatment. Questions: What is the recommended dose of Vyndamax? Is Vyndamax 61 mg equivalent to Vyndaqel 80 mg? What should patients do if they miss a Vyndamax dose? Can Vyndamax capsules be crushed or cut? 1 further question follow. 5 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Dosing and administration questions

Manufacturer: Pfizer Inc  
Prescribing information: [Vyndaqel and Vyndamax](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685)

## Dosing

<a id="vyndamax-dose"></a>

### What is the recommended dose of Vyndamax?

> “The recommended dosage is either VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily or VYNDAMAX 61 mg (one 61-mg tafamidis capsule) orally once daily.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=The%20recommended%20dosage%20is%20either%20VYNDAQEL,tafamidis%20capsule%29%20orally%20once%20daily.)

> “VYNDAMAX and VYNDAQEL are not substitutable on a per mg basis [see Clinical Pharmacology (12.3)].”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=orally%20once%20daily.-,VYNDAMAX%20and%20VYNDAQEL%20are%20not%20substitutable%20on%20a%20per%20mg,basis%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

> “No dose titration is required<sup>1</sup>”

Source: [VYNDAMAX: Dosing Information for VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/dosing#:~:text=No%20dose%20titration%20is)

<a id="vyndamax-61mg-vs-vyndaqel-80mg"></a>

### Is Vyndamax 61 mg equivalent to Vyndaqel 80 mg?

> “VYNDAMAX and VYNDAQEL are not substitutable on a per mg basis [see Clinical Pharmacology (12.3)].”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=orally%20once%20daily.-,VYNDAMAX%20and%20VYNDAQEL%20are%20not%20substitutable%20on%20a%20per%20mg,basis%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

> “No clinically significant differences in steady state Cmax and area under the plasma concentration over time curve (AUC) of tafamidis were observed for VYNDAMAX 61-mg capsule compared to VYNDAQEL administered as four 20-mg capsules.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=No%20clinically%20significant%20differences%20in,administered%20as%20four%2020%2Dmg%20capsules.)

> “a single VYNDAMAX 61-mg capsule is bioequivalent<sup>†</sup> to VYNDAQEL 80 mg (four 20-mg capsules) and is not interchangeable on a per-mg basis.<sup>1-3</sup>”

Source: [VYNDAMAX: Clinical Efficacy in ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/efficacy-data#:~:text=a%20single%20VYNDAMAX%2061%2Dmg%20capsule,not%20interchangeable%20on%20a%20per%2Dmg)

> “As determined by the predefined 90% confidence interval criteria of 80% to 125% bioequivalence limits for tafamidis area under curve (AUC) and peak plasma concentration (Cmax) after repeated oral daily dosing for 7 days.<sup>2</sup>”

Source: [VYNDAMAX: Clinical Efficacy in ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/efficacy-data#:~:text=As%20determined%20by%20the%20predefined,oral%20daily%20dosing%20for%207)

Note: The label and the Vyndamax HCP site state that one VYNDAMAX 61-mg capsule and VYNDAQEL 80 mg (four 20-mg capsules) give similar steady-state tafamidis exposure; the label also states that the two products are not substitutable on a per mg basis. The bioequivalence study the site cites (Lockwood et al., Clin Pharmacol Drug Dev 2020) was conducted in healthy volunteers.

<a id="vyndamax-missed-dose"></a>

### What should patients do if they miss a Vyndamax dose?

> “If a dose is missed, instruct patients to take the dose as soon as remembered or to skip the missed dose and take the next dose at the regularly scheduled time. Do not double the dose.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=If%20a%20dose%20is%20missed%2C,Do%20not%20double%20the%20dose.)

## Administration

<a id="vyndamax-swallow-whole"></a>

### Can Vyndamax capsules be crushed or cut?

> “The capsules should be swallowed whole and not crushed or cut.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=The%20capsules%20should%20be%20swallowed%20whole%20and%20not%20crushed%20or%20cut.)

## Taking treatment

<a id="vyndamax-vitamin-a"></a>

### Does Vyndamax require a vitamin A supplement?

> “No supplemental treatment, such as a daily vitamin A supplement, is required.<sup>1</sup>”

Source: [VYNDAMAX: Dosing Information for VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/dosing#:~:text=No%20supplemental%20treatment%2C%20such%20as%20a%20daily%20vitamin%20A%20supplement%2C%20is)

## Related pages
- [Medical information: Vyndamax (tafamidis): Transthyretin amyloid cardiomyopathy](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy)
- [Indication](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/safety)
- [Specific populations](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/guidelines)
